Krystal Biotech, Inc. (BVMF:K1YS34)
Brazil · Delayed Price · Currency is BRL | Market Cap | 46.38B +49.3% |
| Revenue (ttm) | 2.43B +26.0% |
| Net Income | 1.17B +13.2% |
| EPS | 1.35 +10.5% |
| Shares Out | n/a |
| PE Ratio | 41.98 |
| Forward PE | 30.86 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 56.70 |
| Previous Close | 56.70 |
| Day's Range | 56.70 - 56.70 |
| 52-Week Range | 44.80 - 59.94 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 2, 2026 |
About Krystal Biotech
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical trials for treating cystic fibrosis; KB111 for Hailey... [Read more]
Financial Performance
In 2025, Krystal Biotech's revenue was $389.13 million, an increase of 33.94% compared to the previous year's $290.52 million. Earnings were $204.83 million, an increase of 129.74%.
Financial numbers in USD Financial StatementsNews
Krystal Biotech price target lowered to $380 from $403 at TD Cowen
TD Cowen lowered the firm’s price target on Krystal Biotech (KRYS) to $380 from $403 and keeps a Buy rating on the shares. The firm updated its model following Q3…
Krystal Biotech price target lowered to $375 from $400 at RBC Capital
RBC Capital lowered the firm’s price target on Krystal Biotech (KRYS) to $375 from $400 and keeps an Outperform rating on the shares after its Q3 results. While the pipeline…
Krystal Biotech price target lowered to $412 from $416 at Citi
Citi lowered the firm’s price target on Krystal Biotech (KRYS) to $412 from $416 and keeps a Buy rating on the shares. The quarter was bittersweet with positives including favorable…
Krystal Biotech falls -13.9%
Krystal Biotech (KRYS) is down -13.9%, or -$46.21 to $286.08.
H.C. Wainwright positive on Krystal despite pipeline timing updates
H.C. Wainwright analyst Joseph Pantginis views Krystal Biotech’s (KRYS) Q3 as solid, with VYJUVEK net revenue of $127.3M led by international growth, and believes the completed pricing negotiations in...
Krystal Biotech falls -11.7%
Krystal Biotech (KRYS) is down -11.7%, or -$38.96 to $293.33.
Krystal pipeline catalysts experiencing delays, says RBC Capital
RBC Capital views Krystal Biotech’s (KRYS) Q3 report as mixed despite the Vyjuvek beat, saying the company shared that some pipeline program catalysts are experiencing delays. The dystrophic epidermol...
Krystal Biotech Earnings Call Transcript: Q3 2026
Global VYJUVEK revenue grew 30% YoY to $127.3M, with $63.1M net income and more than $1.2B in cash and investments. Clinical progress continued, though several readouts shifted into 2027; guidance was lowered and a $400M buyback authorized.
Krystal Biotech Earnings release: Q3 2026
Krystal Biotech released its Q3 2026 earnings on November 2, 2026, summarizing the period's financial results.
Krystal Biotech Quarterly report: Q3 2026
Krystal Biotech has published its Q3 2026 quarterly earnings report on November 2, 2026.
Krystal Biotech Slides: Q3 2026
Krystal Biotech has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on November 2, 2026.
Krystal Biotech announces $400M share repurchase program
The company also announced that its board of directors has authorized a share repurchase program under which Krystal may repurchase up to $400M of its outstanding common stock. Published first…
Krystal Biotech reports Q3 EPS $2.05, consensus $1.92
Reports Q3 revenue $127.34M, consensus $126.54M. “Continued growth in Vyjuvek revenue is supporting profitability and funding the advancement of our pipeline,” said Krish S. Krishnan, chairman and CEO...
Krystal Biotech Announces Third Quarter 2026 Financial and Operating Results
$127.3 million in 3Q VYJUVEK global revenue and $1.1 billion since launch VYJUVEK pricing negotiations in Germany and Italy completed KB113 clinical data demonstrate regression in more than 80% of ass...
Krystal Biotech to Report Third Quarter 2026 Financial Results on November 2, 2026
PITTSBURGH, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that it will report its third quarter 2026 financial results on Monday, November 2, 2...
Krystal Biotech price target raised to $416 from $386 at Citi
Citi raised the firm’s price target on Krystal Biotech (KRYS) to $416 from $386 and keeps a Buy rating on the shares after the company announced a clinical update supporting…
Krystal Biotech provides clinical data for KB113 program
Krystal Biotech (KRYS) announced a clinical update supporting initial proof of concept for KB113, an intratumoral immunotherapy designed to drive sustained, localized expression of interleukin-2, or I...
Krystal Biotech Announces Positive Clinical Data for New Dermatology Program KB113 Demonstrating Broad Basal Cell Carcinoma Regression in Patients with Gorlin Syndrome
Over 80% of assessed basal cell carcinoma lesions regressed across three Gorlin syndrome patients treated with KB113 Substantial regression was observed in lesions not directly injected with KB113, co...
Krystal Biotech resumed with a Buy at Goldman Sachs
Goldman Sachs analyst Andrea Newkirk resumed coverage of Krystal Biotech (KRYS) with a Buy rating and $441 price target Goldman resumed coverage of the biotechnology sector, saying the group has…
Krystal Biotech price target raised to $400 from $392 at BofA
BofA analyst Alec Stranahan raised the firm’s price target on Krystal Biotech (KRYS) to $400 from $392 and keeps a Buy rating on the shares. Despite falling off all-time highs…
Krystal Biotech Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
The company is expanding its commercial genetic medicines portfolio, with VYJUVEK performing well in the U.S. and early launches in Europe and Japan. Pipeline programs in dermatology, ophthalmology, and pulmonary/oncology are advancing, with key data readouts expected within a year. Financial stability allows for continued R&D without new financing.
Krystal Biotech to Present at 2026 Cantor Global Healthcare Conference
PITTSBURGH, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) today announced that the Company will participate in the 2026 Cantor Global Healthcare Conference on...
Krystal Biotech initiated with an Outperform at RBC Capital
RBC Capital analyst Lisa Walter initiated coverage of Krystal Biotech (KRYS) with an Outperform rating and $400 price target Krystal is a gene therapy company focused on rare diseases treatable…
Krystal Biotech price target lowered to $392 from $396 at BofA
BofA analyst Alec Stranahan lowered the firm’s price target on Krystal Biotech (KRYS) to $392 from $396 and keeps a Buy rating on the shares after a “mixed” Q2 report.
Krystal Biotech price target raised to $386 from $378 at Citi
Citi analyst Yigal Nochomovitz raised the firm’s price target on Krystal Biotech (KRYS) to $386 from $378 and keeps a Buy rating on the shares.